Congratulations, Dr. Peralta and team!
Chief Medical Officer Habitat Health, Professor of Medicine UCSF, Internal Medicine &Nephrology #PACE #equity #value-based care
I am so excited about our new paper, work led by Dr. Michelle Odden and team. Frail elderly persons in long term care are an understudied population. As our elderly population grows, we need better data that reflects the heterogeneity in this group!
Nonprofit Executive | Care Management Leader | Passionate Advocate | Licensed Master Social Worker
Nice work, Emory University! The newly funded consortium will be called the Southeast Integrative Newborn Screening—Long-Term Follow-Up Consortium. One primary goal is to focus on efforts that ensure NBS specimens are collected efficiently, no more than two days after birth. To achieve that, a secure data exchange infrastructure will be implemented regionally and nationally. The other main goal is to identify and develop data elements for specific disorders that can be used to make it easier for families to access treatment and information once NBS has identified a condition, and improve long-term outcomes. The only nationally funded multistate consortium, it includes health departments in Georgia, Florida, Louisiana, and Mississippi, along with partnerships with states in the Southeastern Regional Genetics Group. https://lnkd.in/gRruMcm8
A member of the ADACC Network, Dr. Ambar Kulshreshtha, is the first author of a cross-sectional study published in JAMA Network Open. He worked with other contributors, like Dr. Nicole Fowler, to answer, “What is the prevalence of unrecognized cognitive impairment among patients at federally qualified health centers?” Their findings suggest “that unrecognized cognitive impairment is ubiquitous among individuals from underrepresented minoritized groups and socially vulnerable older adults receiving primary care from federally qualified health centers.” 🧠 Read more: https://lnkd.in/g76dF58d
A team headed by a University of Florida Health researcher, who has dedicated 20 years to studying the placenta, is developing the first therapy that could possibly reverse a condition which is a major cause of stillbirth and premature delivery worldwide. When the placenta fails, induced labor or cesarean delivery frequently becomes the sole solution. https://gag.gl/wtVHaP
A team led by a University of Florida Health researcher, who has dedicated 20 years to studying the placenta, is developing the first therapy that might reverse a condition which significantly contributes to stillbirth and premature delivery worldwide. When the placenta fails, induced labor or cesarean delivery is frequently the sole option for premature delivery. https://gag.gl/wtVHaP
A team headed by a University of Florida Health researcher, who has dedicated 20 years to studying the placenta, is developing the first therapy that might reverse a condition significantly contributing to stillbirth and premature delivery worldwide. When the placenta fails, induced labor or cesarean delivery often becomes the sole solution. https://gag.gl/wtVHaP
Oncology/Hematology/Nuclear Medicine/Pharmaceutical Marketing/ Board Certified Physician/ Pharma Leader
A team led by a University of Florida Health researcher, who has dedicated 20 years to studying the placenta, is developing the first therapy that could potentially reverse a condition significantly contributing to stillbirth and premature delivery worldwide. When the placenta fails, induced labor or cesarean delivery frequently becomes the sole option for premature delivery. https://gag.gl/wtVHaP
A team led by a University of Florida Health researcher, who has dedicated 20 years to studying the placenta, is developing the first therapy that might reverse a condition significantly contributing to stillbirth and premature delivery worldwide. When the placenta fails, induced labor or cesarean delivery frequently becomes the sole option for premature delivery. https://gag.gl/wtVHaP
A team led by a University of Florida Health researcher, who has dedicated 20 years to studying the placenta, is developing the first therapy that might reverse a condition known for causing stillbirth and premature delivery worldwide. When the placenta fails, inducing labor or performing a cesarean delivery is frequently the sole option. https://gag.gl/wtVHaP
Laurent Glance, M.D., Pat Stone, Jingjing Shang, PhD, RN, FAAN, Ashley Chastain, DrPH, MPH and other research team members recently had their paper "Hospital Strain During the COVID-19 Pandemic and Outcomes in Older Racial and Ethnic Minority Adults" published in JAMA Network Open. The findings of this study suggest that older adults hospitalized with sepsis in hospitals under severe stress were more likely to experience adverse outcomes as the hospital COVID-19 burden increased, and these increases were greater among racial and ethnic minoritized individuals. Please click here to read the full paper: https://lnkd.in/eJDqgdvx.
A team led by a University of Florida Health researcher, who has dedicated 20 years to studying the placenta, is developing the first therapy that might reverse a condition known to be a major cause of stillbirth and premature delivery worldwide. When the placenta fails, induced labor or cesarean delivery often becomes the only solution. https://gag.gl/wtVHaP
